Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD)

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Facioscapulohumeral Muscular Dystrophy

In brief

Study A083-02 is a multi-center, Phase 2 study to evaluate the safety, tolerability, pharmacodynamics (PD), efficacy, and pharmacokinetics (PK) of locally-acting ACE-083 in patients with Facioscapulohumeral muscular dystrophy (FSHD) to be conducted in two parts. Part 1 is open-label, dose-escalation and Part 2 is randomized, double-blind, and placebo-controlled.

Key facts

Study ID
NCT02927080
Run by
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
People needed
95
Starts
2016-11-01
Expected to finish
2019-10-09
Last updated by the study team
2022-09-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.